Evidence map›Paper›PMID 26280397›Full record

ReviewThe Journal of membrane biology2015

Pharmacological Inhibition of Protein Lipidation.

Lakshmi Ganesan, Ilya Levental

Abstract readReview
In one paragraph

Review in The Journal of membrane biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Serum biomarkers for diagnosis and prediction of type 1 diabetes.Translational research : the journal of laboratory and clinical medicine · 2018
    Review
  6. Efficient farnesylation of an extended C-terminal C(The Journal of biological chemistry · 2018
    Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lakshmi GanesanUniversity of Texas Medical School, Houston, TX, USA.
Ilya LeventalUniversity of Texas Medical School, Houston, TX, USA. ilya.levental@uth.tmc.edu.

Funding

Lipidomic, biophysical, and functional differentiation of Mesenchymal Stem Cell membranesR01GM114282 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LEVENTAL, ILYA · 2015 to 2019
$1.7M
NIGMS NIH HHS R01 GM114282
6 · The paper itself

Abstract

Lipid modifications of mammalian proteins are widespread, modifying thousands of targets involved in all aspects of cellular physiology cellular physiology. Broadly, lipidations serve to increase protein hydrophobicity and association with cellular membranes. Often, these modifications are absolutely essential for protein stability and localization, and serve critical roles in dynamic regulation of protein function. A number of lipidated proteins are associated with diseases, including parasite infections, neurological diseases, diabetes, and cancer, suggesting that lipid modifications represent potentially attractive targets for pharmacological intervention. This review briefly describes the various types of posttranslational protein lipid modifications, proteins modified by them, and the enzymatic machinery associated with these. We then discuss several case studies demonstrating successful development of lipidation inhibitors of potential (and more rarely, realized) clinical value. Although this field remains in its infancy, we believe these examples demonstrate the potential utility of targeting protein lipidation as a viable strategy for inhibiting the function of pathogenic proteins.

Indexed as

LipidsAnimalsDrug DiscoveryHumansLipid MetabolismMolecular Targeted TherapyProtein Processing, Post-TranslationalProteinsLipidsProteinsLipid raftMembrane bindingMicrodomainPost-translational modificationProtein lipidationSubcellular localization

Identifiers

PMID26280397
PMCPMC4618097

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.